Japan has the second largest healthcare market in the world. Market growth factors include the rise of chronic diseases, an aging population and the increase of home-based care as a result. Globally, Japan has the highest percentage of citizens over the age of 65 - a figure that is also growing more rapidly than in western nations.
Asia’s increasing economic development drives a new medical device industry, particularly in Japan, China, Vietnam, and Malaysia. The Southeast Asian medical device market is expected to grow to $10 billion by 2020.
The rapidly expanding markets in Asia also fuel continuous regulatory changes that focus on streamlining and optimizing testing and monitoring processes worldwide. Rigorous long-term monitoring and reporting of adverse effects is required after the device becomes available on the market.
“The incorporation of genae Japan, with HQ in Tokyo, illustrates our commitment and ability to provide high quality research services on a global scale”, said Bart Segers, genae’s CEO. “The Greater Tokyo Area is a vast economic region that supports a population of 36 million people. Tokyo boasts a wealth of capable individuals and companies with excellent technologies.”
About the genae group
genae is involved in the development and commercialization of medical devices, biologics and therapies that change medical practice. As a full service CRO and services provider for the medical industries, genae aims at improving health and quality of life by innovating and accelerating high quality research. genae's Quality Management System is ISO 9001 compliant, has been tested rigorously and continues to pass regulatory and sponsor’s audits and inspections.
genae associates nv is a privately held company with principal offices in Antwerp, Belgium and is part of the genae group, the medical device CRO.
To learn more about genae, please visit www.genae.com.
genae associates nv
Bart Segers, CEO
+32 475 566 780
Justitiestraat 6B, 2018 Antwerp, Belgium